Medvin Clinical Research - Whittier

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Rheumatoid arthritis4 trials
• Obesity2 trials
• Psoriasis2 trials
• Psoriatic arthritis2 trials
• Osteoarthritis1 trial

Phase

• Phase 43 trials
• Phase 22 trials
• Phase 31 trial

Status

• Completed3 trials
• Active, not recruiting2 trials
• Not yet recruiting1 trial
• Terminated1 trial

Lead sponsor

• Eli Lilly and Company5 trials
• Aqtual, Inc.1 trial
• Pacira Pharmaceuticals, Inc1 trial

Running trials

• Active, not recruiting

  A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

  NCT06864026· Phase 4· Eli Lilly and Company· Source

• Recruiting

  A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee

  NCT06884865· Phase 2· Pacira Pharmaceuticals, Inc· Source

  Contact: Tien-I Karleen Su (principal investigator)

• Active, not recruiting

  Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to a DMARD Starting a New bDMARD or tsDMARD Treatment +/- csDMARD

  NCT05936970· Aqtual, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Osteoarthritis1 recruiting

Closed trials

• Terminated

  A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis

  NCT06859294· Phase 2· Eli Lilly and Company· Source

• Completed

  Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

  NCT06588296· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Baricitinib in Participants With Rheumatoid Arthritis

  NCT04086745· Phase 4· Eli Lilly and Company· Source

• Completed

  A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

  NCT03915964· Phase 4· Eli Lilly and Company· Source